Immunocore To Tap Into HTA Advice To Ensure IMCgp100 Success
This article was originally published in The Pink Sheet Daily
Executive Summary
British immunotherapy specialist Immunocore plans to make full use of the scientific advice European HTAs are offering to help it progress its lead product IMCgp100 through the European Medicines Agency's Adaptive Pathways pilot program.
You may also be interested in...
Jallal To Lead Immunocore, Building On Partnership She Forged At MedImmune
A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.
Few UK "Promising Innovative Medicine" Holders Seek Joint MHRA/NICE Advice – Rawlins
MHRA chief says too few drug makers granted PIM designation on the basis of early clinical data are making use of joint consultations with the agency and the cost-effectiveness watchdog NICE.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.